Stay updated with breaking news from Contract research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) major shareholder Braden Michael Leonard acquired 1,000,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The stock was bought at an average price of $1.08 per share, for a total transaction of $1,080,000.00. Following the purchase, the insider now owns 10,395,934 shares in […] ....
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) major shareholder Braden Michael Leonard acquired 528,621 shares of the stock in a transaction on Thursday, June 13th. The shares were acquired at an average price of $1.15 per share, with a total value of $607,914.15. Following the transaction, the insider now directly owns 11,007,134 shares of […] ....
Bain Capital Life Sciences Investors LLC boosted its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,500,000 shares of the biotechnology company’s stock after purchasing an […] ....
REDDING, Calif., May 29, 2024 /PRNewswire/ According to a new market research report titled, "High Throughput Screening Market by Technology (Cell-based Assays [2D, 3D], Label-free, Lab-on-chip) ....